ArticleCommunications biology2025
Targeting TDP1 phosphorylation by the natural product imperatorin promotes DNA repair and cardiac regeneration.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Imperatorin Nanostructured Lipid Carriers with Grape Seed Oil for Boosting Oral Absorption and Antioxidant Capacity.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Promoting cardiomyocyte proliferation is a highly promising strategy to repair the damaged myocardium and treat myocardial infarction (MI). DNA damage is a key factor leading to cell cycle arrest in cardiomyocytes, and DNA repair is required to relieve the restriction of proliferation. However, the potential of natural small-molecule compounds to enhance DNA repair and proliferation in cardiomyocytes has not been fully explored. Through screening of natural products, we found imperatorin could stimulate cardiomyocyte DNA repair and proliferation both in vitro and in vivo, which resulted in a significant improvement in cardiac function. By virtual prediction of pharmacological targets, we found that the target protein of imperatorin was the DNA repair protein tyrosyl-DNA phosphodiesterase 1 (TDP1). In terms of mechanism, imperatorin enhanced the phosphorylation of TDP1 at serine 81 by facilitating the proximity-mediated interaction between TDP1 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Collectively, these findings suggest that imperatorin is a promising lead for the development of cardiac regeneration agents, and TDP1 is a hitherto unrecognized potential therapeutic target for MI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.